Retrospective Observational Single-Center Study of Complications of Arterial Indwelling Catheters for Invasive Blood Pressure in Intensive Care Unit Patients

Angiology ◽  
2021 ◽  
pp. 000331972110521
Author(s):  
Conrado Dias Pacheco Annicchino Baptistella ◽  
Cynthia de Almeida Mendes ◽  
Marcela Juliano Silva ◽  
Nelson Wolosker

This study aimed to analyze the incidence of complications resulting from the use of an indwelling arterial catheter (IAC). We compared the characteristics of the patients with an IAC who developed complications with those who did not present any complications. The study included 1,869 patients with an IAC hospitalized in intensive care units (ICUs) between 2017 and 2018. Most patients were male (58.7%), in the seventh decade of life, and had systemic arterial hypertension. The most common site of IAC implantation was the radial artery. Fifty-four (2.88%) cases of complications related to an IAC were identified including bleeding, hematomas, and thrombosis. Female patients had a higher risk of complications ( P = .030). Comorbidities such as arrhythmias ( P < .001) and peripheral arterial disease ( P = .041) also increased that risk. The use of vasoactive drugs ( P = .001), hemodialysis ( P = .001), and orotracheal intubation (OTI) ( P = .001) was significantly associated with the occurrence of complications as well as length of stay in ICUs ( P < .001) and IAC duration ( P = .001). IACs are safe devices commonly used in ICUs, with an incidence of complications of 2.88%.

Hematology ◽  
2021 ◽  
Vol 26 (1) ◽  
pp. 328-339
Author(s):  
Tuğba Barlas ◽  
Kamil İnci ◽  
Gulbin Aygencel ◽  
Melda Türkoğlu ◽  
Özlem Güzel Tunçcan ◽  
...  

Viruses ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1253
Author(s):  
Andrey A. Ivashchenko ◽  
Valeria N. Azarova ◽  
Alina N. Egorova ◽  
Ruben N. Karapetian ◽  
Dmitry V. Kravchenko ◽  
...  

COVID-19 is a contagious multisystem inflammatory disease caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We studied the efficacy of Aprotinin (nonspecific serine proteases inhibitor) in combination with Avifavir® or Hydroxychloroquine (HCQ) drugs, which are recommended by the Russian Ministry of Health for the treatment therapy of moderate COVID-19 patients. This prospective single-center study included participants with moderate COVID-19-related pneumonia, laboratory-confirmed SARS-CoV-2, and admitted to the hospitals. Patients received combinations of intravenous (IV) Aprotinin (1,000,000 KIU daily, 3 days) and HCQ (cohort 1), inhalation (inh) treatment with Aprotinin (625 KIU four times per day, 5 days) and HCQ (cohort 2) or IV Aprotinin (1,000,000 KIU daily for 5 days) and Avifavir (cohort 3). In cohorts 1–3, the combination therapy showed 100% efficacy in preventing the transfer of patients (n = 30) to the intensive care unit (ICU). The effect of the combination therapy in cohort 3 was the most prominent, and the median time to SARS-CoV-2 elimination was 3.5 days (IQR 3.0–4.0), normalization of the CRP concentration was 3.5 days (IQR 3–5), of the D-dimer concentration was 5 days (IQR 4 to 5); body temperature was 1 day (IQR 1–3), improvement in clinical status or discharge from the hospital was 5 days (IQR 5–5), and improvement in lung lesions of patients on 14 day was 100%.


Sign in / Sign up

Export Citation Format

Share Document